This guest editorial is by Pooja Dhoundiyal, Research Manager, Vyansa Intelligence
Drug development is becoming increasingly dependent on the ability to generate reliable biological evidence that supports stronger clinical decisions, regulatory confidence, and therapeutic advancement. Complex therapies, precision medicine approaches, and targeted treatments require deeper analytical understanding before pharmaceutical companies can make critical decisions around patient selection, clinical progression, and regulatory readiness.
Clinical laboratory services are moving beyond their traditional role of sample analysis and reporting. Their capabilities now influence how quickly sponsors can identify suitable patient populations, validate therapeutic approaches, monitor treatment response, and generate evidence required throughout the development lifecycle.
The expanding demand for advanced laboratory capabilities reflects this strategic shift. The global clinical laboratory services market was valued at USD 80 billion in 2025 and is estimated at USD 198 billion in 2026. It is projected to reach USD 350.92 billion by 2032, supported by increasing adoption of specialized testing, molecular diagnostics, and advanced analytical platforms. For pharmaceutical organizations, laboratory selection is no longer limited to operational availability. The ability to convert complex biological information into actionable insights is becoming closely linked with development efficiency, clinical confidence, and therapeutic advancement.
Drug Development Velocity Now Depends on Evidence Quality
Modern drug development programs increasingly rely on biological evidence generated throughout the therapeutic lifecycle. The shift toward precision medicines, biologics, and advanced therapies has increased the need for accurate insights into disease mechanisms, patient characteristics, and treatment responses.
Clinical laboratory services support several critical development decisions, including:
- Identifying biomarkers linked with therapeutic response.
- Supporting patient stratification strategies.
- Evaluating clinical trial endpoints.
- Monitoring treatment outcomes.
- Enabling companion diagnostic approaches.
The impact is particularly significant in targeted therapies, where the ability to identify the appropriate patient population can determine trial efficiency and development progress. Laboratory-generated evidence increasingly influences decisions before and during clinical trials rather than serving only as a confirmation step after treatment administration. This change places laboratory capabilities closer to the strategic core of drug development.
Companion diagnostics have become increasingly integrated into oncology development pathways, where molecular testing helps identify patients most likely to benefit from specific therapies. The relationship between diagnostic capability and therapeutic advancement demonstrates how laboratory performance can directly influence development timelines.
Laboratory Partnerships Are Moving Beyond Testing Capacity
Pharmaceutical companies are changing how they evaluate laboratory partners. Testing availability and turnaround time remain important, but complex development programs require broader capabilities.
For procurement and external manufacturing leaders, partner evaluation increasingly includes:
Scientific capabilities
- Specialized assay expertise.
- Experience supporting complex therapeutic areas.
- Ability to manage advanced analytical requirements.
Operational execution
- Global clinical trial support.
- Consistent workflows across locations.
- Scalable laboratory infrastructure.
Data capabilities
- Integration with clinical development systems.
- Secure management of laboratory-generated information.
- Efficient data interpretation.
The shift toward capability-based partnerships is visible across the laboratory services ecosystem. Precision for Medicine and PathAI established a collaboration focused on integrating AI-powered digital pathology capabilities into clinical trial and biospecimen services. The collaboration reflects a broader movement where pharmaceutical sponsors increasingly seek laboratory partners that combine analytical expertise with technology-enabled solutions.
Laboratory providers are therefore being assessed less as testing suppliers and more as strategic contributors capable of supporting complex development programs.
Data Reliability Shapes Regulatory Confidence
Speed in drug development depends not only on generating data but also on ensuring that data can support confident decisions. Laboratory-generated evidence must meet increasingly demanding expectations around consistency, traceability, and analytical reliability. For quality and CMC teams, laboratory performance is closely connected with:
- Analytical method validation.
- Reproducibility of results.
- Standardized operating procedures.
- Data integrity throughout the testing process.
- Reliable sample management.
A laboratory result has limited value if it cannot be consistently reproduced or incorporated into a broader regulatory evidence package. Digital pathology adoption illustrates how pharmaceutical and laboratory organizations are strengthening analytical consistency. Labcorp’s collaboration with Roche to advance digital pathology capabilities focuses on improving pathology workflows and creating greater opportunities for technology-enabled laboratory analysis.
The move toward standardized digital workflows demonstrates how laboratory infrastructure is becoming increasingly important in supporting reliable evidence generation across development programs.
Precision Medicine Raises Analytical Expectations
The expansion of precision medicine is increasing the technical requirements placed on clinical laboratory services. Therapies designed around specific molecular characteristics require analytical capabilities that extend beyond conventional testing models.
Key capabilities supporting this evolution include:
- Next-generation sequencing enables deeper molecular profiling and supports targeted therapeutic strategies.
- Molecular diagnostics helps identify biological markers linked with treatment decisions.
- Digital pathology improves the analysis of complex tissue-based information.
- Multiplex testing allows evaluation of multiple biological indicators within a single workflow.
The clinical laboratory services landscape is increasingly influenced by molecular diagnostics, genetic testing, pathology, and specialty testing capabilities as pharmaceutical companies develop therapies requiring more detailed biological insights.
Artificial intelligence is also becoming integrated into laboratory workflows. Lunit and CellCarta have partnered to incorporate AI pathology solutions into clinical trial workflows, expanding access to AI-supported biomarker and pathology analysis for pharmaceutical research programs.
The importance of these technologies extends beyond automation. Their value lies in improving the speed and depth of interpretation required for increasingly complex therapeutic development.
Pharma Outsourcing Evolves Toward Capability-Based Collaboration
The relationship between pharmaceutical companies and laboratory providers is moving away from transactional outsourcing models. Development teams are increasingly looking for partners that can contribute scientific knowledge, operational reliability, and technology capabilities throughout the lifecycle of a program.
The evaluation framework is shifting from:
| Traditional Considerations | Strategic Considerations |
| Testing availability | Scientific expertise |
| Processing capacity | Analytical innovation |
| Short-term cost efficiency | Long-term development value |
| Individual services | Integrated capabilities |
For procurement teams, this means supplier selection increasingly requires a broader assessment of technical depth, quality maturity, and scalability. External manufacturing and clinical operations leaders are also placing greater emphasis on laboratory partners that can support global programs while maintaining consistent standards across regions.
The ability to provide reliable evidence at the right stage of development is becoming a defining factor in pharmaceutical partnerships.
Development Speed Will Depend on Laboratory Intelligence
The next phase of pharmaceutical development will be shaped by how effectively organizations manage scientific complexity and convert biological information into actionable evidence. Clinical laboratory services are becoming a critical determinant of development velocity by supporting faster decisions, stronger regulatory confidence, and more precise therapeutic strategies.
For pharmaceutical leaders, the priority is shifting from selecting laboratories based only on testing capability toward building partnerships that strengthen the entire development pathway. Organizations that integrate laboratory expertise earlier into clinical and development strategies will be better positioned to navigate complex therapies and accelerate the journey from discovery to patients.
Pooja Dhoundiyal is a research manager at Vyansa Intelligence with over 10 years of experience in market research, strategic intelligence, and industry analysis. She specializes in delivering data-driven insights, competitive benchmarking, and market forecasting across diverse industry verticals. At Vyansa Intelligence, she leads research initiatives focused on developing comprehensive market studies, trend analyses, and actionable advisory solutions for global clients.
